BIO logo

Bio-Rad Laboratories (BIO)

Profile

Full Name

Bio-Rad Laboratories, Inc.

Ticker Symbol

BIO

Exchange

NYSE

Sector

Healthcare

Industry

Medical Devices

Country

United States

IPO

February 27, 1980

Indexes

Not included

Website

http://www.bio-rad.com

Employees

7700

Key Details

Price

$242.63(-2.85%)

Market cap

$6.80B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.57B(-3.92% YoY)

Annual EPS

-$65.36(-199.54% YoY)

PE ratio

-

Next earnings date

May 1, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$242.63
BIO price is $242.63

30-Day Relative Volume

0.92
BIO 30-day relative volume is 0.92

Price Performance

Price Most recent change

-2.85%
BIO price was down -2.85% on Apr 25, 2025

Price YTD change

-26.14%
BIO price is down -26.14% since January 1st

Price 1-year change

-11.96%
BIO price is down -11.96% year-on-year

Price 3-year change

-54.22%
BIO price is down -54.22% over the past 3 years

Price Range

Price All-time high

$832.70
BIO price is currently -70.86% below its historical high of $832.70

Price 3-year low

$215.38
BIO price is currently +12.65% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$6.80B
BIO market capitalization is $6.80 billion

Market cap 3-year change

-57.17%
BIO market capitalization is down -57.17% over the past 3 years

Market cap All-time high

$24.59B
BIO market capitalization is currently -72.36% below its historical high of $24.59 billion

Market cap sector rank

90.64%
BIO market capitalization is higher than 90.64% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-1.8%
BIO shares outstanding is down -1.8% year-on-year

Shares Outstanding 3-Year Change

-6.45%
BIO shares outstanding is down -6.45% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.92
BIO beta is 0.92

200-day SMA

$313.98
BIO price is currently -22.72% below its 200-day simple moving average

50-day SMA

$254.12
BIO price is currently -4.52% below its 50-day simple moving average

RSI

47.13
BIO 14-day relative strength index is 47.13

Volume

0.92
BIO 30-day relative volume is 0.92

ATR

$11.02
BIO average true range is $11.02

10-day Historical Volatility

43.80%
BIO 10-day historical volatility is 43.80%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.57B
BIO annual revenue is $2.57 billion

Revenue Analysts estimate

$2.57B
BIO annual revenue is currently +0.03% higher than the consensus analysts' forecast

Revenue 1-year change

-3.92%
BIO annual revenue is down -3.92% year-on-year

Revenue Sector rank

86.69%
BIO annual revenue is higher than 86.69% of companies in Healthcare sector

EPS

EPS

-$65.36
BIO annual earnings per share is -$65.36

EPS Analysts estimate

$9.52
BIO annual earnings per share is currently -786.25% lower than the consensus analysts' forecast

EPS 1-year change

-199.54%
BIO annual earnings per share is down -199.54% year-on-year

EPS Sector rank

3.17%
BIO annual earnings per share is higher than 3.17% of companies in Healthcare sector

Profit

Gross profit

$1.38B
BIO annual gross profit is $1.38 billion

Gross margin

53.73%
BIO annual gross profit margin is 53.73%

Operating profit

$269.00M
BIO annual operating income is $269.00 million

Operating margin

10.48%
BIO annual operating profit margin is 10.48%

Net income

-$1.84B
BIO annual net profit is -$1.84 billion

Net margin

-71.86%
BIO annual net profit margin is -71.86%

Expenses

Total expenses

$2.30B
BIO annual total expenses is $2.30 billion

Operating expenses

$1.11B
BIO annual total operating expenses is $1.11 billion

Cost of goods sold

$1.19B
BIO annual cost of goods sold is $1.19 billion

Selling, general & administrative expenses

$814.00M
BIO annual SGA is $814.00 million

Depreciation and amortization

$151.60M
BIO annual depreciation & amortization is $151.60 million

Interest expense

$48.90M
BIO annual interest expense is $48.90 million

Income tax

-$498.30M
BIO annual income tax is -$498.30 million

EBIT & EBITDA

EBIT

-$2.29B
BIO annual earnings before interest & taxes is -$2.29 billion

EBITDA

-$2.14B
BIO annual EBITDA is -$2.14 billion

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$9.36B
BIO annual total assets is $9.36 billion

Non current assets

$6.33B
BIO annual long term assets is $6.33 billion

Current assets

$3.03B
BIO annual total current assets is $3.03 billion

Cash and cash equivalents

$488.10M
BIO annual cash & cash equivalents is $488.10 million

Accounts receivable

$452.50M
BIO annual accounts receivable is $452.50 million

Inventory

$760.00M
BIO annual inventory is $760.00 million

Liabilities

Total liabilities

$2.79B
BIO annual total liabilities is $2.79 billion

Long term liabilities

$2.33B
BIO annual total long term liabilities is $2.33 billion

Current liabilities

$467.80M
BIO annual total current liabilities is $467.80 million

Accounts payable

$122.30M
BIO annual accounts payable is $122.30 million

Debt

Total debt

$1.37B
BIO annual total debt is $1.37 billion

Total debt 1-year change

-2.19%
BIO annual total debt is down -2.19% year-on-year

Long term debt

$1.33B
BIO annual long term debt is $1.33 billion

Short term debt

$42.90M
BIO annual short term debt is $42.90 million

Equity & Capital

Shareholders equity

$6.57B
BIO annual stockholders equity is $6.57 billion

Book value

$6.57B
BIO annual book value is $6.57 billion

Retained earnings

$7.42B
BIO annual retained earnings is $7.42 billion

Working capital

$2.56B
BIO annual working capital is $2.56 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$455.20M
BIO annual cash flow from operations is $455.20 million

Cash from operations 1-year change

+21.42%
BIO annual cash flow from operations is up +21.42% year-on-year

Cash from investing

-$160.20M
BIO annual cash flow from investing activities is -$160.20 million

Cash from investing 1-year change

-893.07%
BIO annual cash flow from investing activities is down -893.07% year-on-year

Cash from financing

-$218.80M
BIO annual cash flow from financing activities is -$218.80 million

Cash from financing 1-year change

+48.59%
BIO annual cash flow from financing activities is up +48.59% year-on-year

CAPEX

CAPEX

$189.00M
BIO annual capital expenditures is $189.00 million

CAPEX 1-year change

+20.61%
BIO annual capital expenditures is up +20.61% year-on-year

Free Cash Flow

Free cash flow

$266.20M
BIO annual free cash flow is $266.20 million

Free cash flow 1-year change

+22%
BIO annual free cash flow is up +22% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

53.73%
BIO annual gross profit margin is 53.73%

Operating margin

10.48%
BIO annual operating profit margin is 10.48%

Net margin

-71.86%
BIO annual net profit margin is -71.86%

ROA & ROE

ROA

-17.03%
BIO annual return on assets is -17.03%

ROE

-24.09%
BIO annual return on equity is -24.09%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
BIO price to earnings ratio value is unknown

PE ratio Sector rank

-
BIO price to earnings ratio is unknown

PB Ratio

PB ratio

1.03
BIO price to book ratio is 1.03

PB ratio Sector rank

42.44%
BIO price to book ratio is higher than 42.44% of companies in Healthcare sector

PS Ratio

PS ratio

2.65
BIO price to sales ratio is 2.65

PS ratio Sector rank

46.49%
BIO price to sales ratio is higher than 46.49% of companies in Healthcare sector

Enterprise value

Enterprise value

$7.68B
BIO enterprise value is $7.68 billion

Enterprise value Sector rank

90.49%
BIO enterprise value is higher than 90.49% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.59
BIO EV/EBITDA is -3.59

EV/EBITDA Sector rank

25.33%
BIO EV/EBITDA is higher than 25.33% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

6.48
BIO annual current ratio is 6.48

Quick ratio

4.85
BIO annual quick ratio is 4.85

Leverage

Debt to equity

0.18
BIO annual debt to equity ratio is 0.18

Interest coverage ratio

-46.90
BIO annual interest coverage ratio is -46.90

Risk & Stability

Piotroski F-Score

6
BIO piotroski f-score is 6

Altman Z-Score

2.36
BIO altman z-score is 2.36

Analyst ratings

Recent major analysts updates

Apr 17, 25 Wells Fargo
Equal-Weight
Feb 12, 25 Wells Fargo
Equal-Weight
Jan 14, 25 RBC Capital
Outperform
Dec 9, 24 RBC Capital
Outperform
Oct 31, 24 RBC Capital
Outperform
Oct 31, 24 Citigroup
Buy
Oct 1, 24 Citigroup
Buy
Aug 27, 24 Wells Fargo
Equal-Weight
Aug 16, 24 RBC Capital
Outperform
Aug 2, 24 RBC Capital
Outperform

Institutional Ownership

Similar stocks

JAZZ logo
Jazz Pharmaceuticals (JAZZ)
BBIO logo
BridgeBio Pharma (BBIO)
LNTH logo
Lantheus Holdings (LNTH)
TGTX logo
TG Therapeutics (TGTX)
RVMD logo
Revolution Medicines (RVMD)
MDGL logo
Madrigal Pharmaceuticals (MDGL)
WAY logo
Waystar Holding (WAY)
ENSG logo
Ensign (ENSG)
LEGN logo
Legend Biotech (LEGN)
  • What is the ticker symbol for Bio-Rad Laboratories?
  • Does Bio-Rad Laboratories pay dividends?
  • What sector is Bio-Rad Laboratories in?
  • What industry is Bio-Rad Laboratories in?
  • What country is Bio-Rad Laboratories based in?
  • When did Bio-Rad Laboratories go public?
  • Is Bio-Rad Laboratories in the S&P 500?
  • Is Bio-Rad Laboratories in the NASDAQ 100?
  • Is Bio-Rad Laboratories in the Dow Jones?
  • When was Bio-Rad Laboratories's last earnings report?
  • When does Bio-Rad Laboratories report earnings?
  • Should I buy Bio-Rad Laboratories stock now?

What is the ticker symbol for Bio-Rad Laboratories?

The ticker symbol for Bio-Rad Laboratories is NYSE:BIO

Does Bio-Rad Laboratories pay dividends?

No, Bio-Rad Laboratories does not pay dividends

What sector is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Healthcare sector

What industry is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Medical Devices industry

What country is Bio-Rad Laboratories based in?

Bio-Rad Laboratories is headquartered in United States

When did Bio-Rad Laboratories go public?

Bio-Rad Laboratories's initial public offering (IPO) was on February 27, 1980

Is Bio-Rad Laboratories in the S&P 500?

No, Bio-Rad Laboratories is not included in the S&P 500 index

Is Bio-Rad Laboratories in the NASDAQ 100?

No, Bio-Rad Laboratories is not included in the NASDAQ 100 index

Is Bio-Rad Laboratories in the Dow Jones?

No, Bio-Rad Laboratories is not included in the Dow Jones index

When was Bio-Rad Laboratories's last earnings report?

Bio-Rad Laboratories's most recent earnings report was on Feb 13, 2025

When does Bio-Rad Laboratories report earnings?

The next expected earnings date for Bio-Rad Laboratories is May 1, 2025

Should I buy Bio-Rad Laboratories stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page